Dalrada Corporation has announced that its Pala Diagnostics LLC joint venture with Vivera Pharmaceuticals Inc performed both reverse transcription-polymerase chain reaction (RT-PCR) tests and US Food and Drug Administration (FDA)-authorized Antigen tests throughout the three-day Boise (NYSE:BZ) Pride Festival and Parade in Idaho.
Dalrada noted that nearly 3,000 point-of-care coronavirus (COVID-19) tests were administered and processed utilizing Vivera’s exclusive proprietary software LabPort, with recipients receiving a text message to retrieve evidence of COVID-19 testing.
“The collaboration between Boise Pride and Pala Diagnostics is a prime example of successfully implementing safety protocols to restore attendance at large public events,” Dalrada CEO Brian Bonar said in a statement.
READ: Dalrada says subsidiary in JV partnership to form Pala Diagnostics to address ongoing demand for coronavirus testing
“Dalrada looks forward to engaging with the community to facilitate safe social congregation, according to recommended public health policy,” Bonar added.
Pala Diagnostics is a diagnostic laboratory with mobile concierge services that provides complete on-site testing for high-volume settings, rapid results within 24-hours for point-of-care PCR testing, and a range of life science testing, including SARS-CoV-2.
Dalrada is a global company specializing in the development of advanced clean energy, healthcare, technology and engineering products and services. With a global footprint in Malaysia, UK, India, and the US, the San Diego, California-based diversified company holds a portfolio of subsidiaries comprising early-stage high growth businesses.
Contact Sean at sean@proactiveinvestors.com